GH Research publishes phase 2b depression drug results in JAMA

March 25, 2026 11:10 AM

GH Research PLC (NASDAQ: GHRS) announced the publication of its Phase 2b trial results for mebufotenin (GH001) in treatment-resistant depression ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found